{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T05:02:50Z","timestamp":1695963770575},"reference-count":5,"publisher":"Massachusetts Medical Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2016,2,25]]},"DOI":"10.1056\/nejmc1515465","type":"journal-article","created":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T16:10:11Z","timestamp":1457367011000},"page":"792-793","source":"Crossref","is-referenced-by-count":2,"title":["Lenalidomide plus Rituximab for Mantle-Cell Lymphoma"],"prefix":"10.1056","volume":"374","member":"150","reference":[{"key":"r001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505237"},{"key":"r002","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.7055"},{"key":"r003","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu264"},{"key":"r004","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.223"},{"key":"r005","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-205013"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMc1515465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T16:30:10Z","timestamp":1494261010000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMc1515465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,25]]},"references-count":5,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,2,25]]}},"alternative-id":["10.1056\/NEJMc1515465"],"URL":"https:\/\/doi.org\/10.1056\/nejmc1515465","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,25]]}}}